Advances in Myelofibrosis Treatments: Insights with Dr. Marina Kremyanskaya

We recently had the pleasure of hosting an informal talk with Dr. Marina Kremyanskaya (Mount Sinai, New York), an expert in Myeloproliferative Neoplasms (MPNs), to discuss the latest insights and challenges in MPN treatment. In this session, Dr. Kremyanskaya shared her extensive knowledge on the current treatment landscape and answered questions from patients and caregivers, offering a unique perspective on the future of MPN care.

Content guide

• Part 1: Discussing PV and ET with Dr. Kremyanskaya

• Part 2: Myelofibrosis Management and Risk Stratification

• Join MPN World for exclusive content!

Part 1: Discussing PV and ET with Dr. Kremyanskaya

In a recent conversation with Dr. Marina Kremyanskaya from Mount Sinai Hospital, we dove into the latest advancements in treating Polycythemia Vera (PV) and Essential Thrombocythemia (ET). The discussion highlighted the importance of patient-specific approaches, particularly when deciding between treatments like interferon or hydroxyurea. For more details, check out the full video with Dr. Kremyanskaya on MPN World. Don’t miss it!

Part 2: Myelofibrosis Management and Risk Stratification

Dr. Kremyanskaya highlighted key factors for risk stratification in Myelofibrosis (MF), such as age, genetic mutations, and blood counts. Latest treatments like JAK inhibitors (e.g., Ruxolitinib and Momelotinib) have made significant progress in managing symptoms like splenomegaly and anemia. For more details, check out the full video with Dr. Kremyanskaya on MPN World. Don’t miss it!

Join MPN World for exclusive content!

For those looking to learn more, join us on MPN World for full access to the insightful video talk with Dr. Kremyanskaya. The platform provides a wealth of information and a supportive community for those affected by MPN. Don’t miss out – connect with us today!